Fenbendazole 222 Mg (Wormiza)

What Is Fenbendazole 222 Mg?

Wormiza 222 Mg is a tablet containing 222 mg of fenbendazole. Fenbendazole is a benzimidazole anthelmintic, which means it belongs to the same broad drug class as albendazole and mebendazole.

Those two are approved for human use, but neither the FDA nor the EMA has approved fenbendazole for human use. In the United States and Europe, it is treated as a veterinary drug, not a standard human medicine.

The 222 mg strength matters because it matches the fenbendazole amount often linked to one Panacur-type 22.2% veterinary unit, which is why this number is widely discussed online.

That said, matching a veterinary reference amount does not make it a validated human dose. Human dosing has not been established in modern regulatory trials.

Wormiza Range – 222mg vs 150mg

Actiza’s Wormiza range includes 222 mg and 150 mg strengths. The active ingredient is the same in both. The difference is the amount of fenbendazole in each tablet. The 222 mg tablet is closer to the widely discussed Panacur-style reference amount.

The 150 mg tablet gives smaller dose steps and may allow finer adjustment if a doctor wants a lower starting point or a more flexible plan. The strength choice is a dosing choice, not a change in drug class or mechanism.

A key point is that there is no approved human “best dose” for fenbendazole. So 222 mg is not “better” in a formal human clinical sense. It is simply the more commonly referenced amount in informal discussions, while 150 mg offers more dose flexibility.

The Benzimidazole Drug Class – Where Fenbendazole 222mg Fits

Fenbendazole belongs to the benzimidazole class. This class includes albendazole, mebendazole, fenbendazole, and oxfendazole. These drugs share a similar core action. They disrupt the parasite’s cell structure by affecting tubulin and microtubules.

The big difference is regulatory status. Albendazole and mebendazole are approved for human use and are listed by WHO as essential medicines. MedlinePlus states that albendazole is used for infections such as neurocysticercosis and hydatid disease, while mebendazole is used for pinworm, roundworm, whipworm, and hookworm infections.

Fenbendazole, in contrast, does not have the same level of human approval. Fenbendazole belongs to the same family but is not in the same regulatory position.

How Fenbendazole 222mg Works (Mechanism of Action)

Fenbendazole works in the same broad way as other benzimidazoles. It damages the structures that parasites need to live, feed, and divide. This is the core reason it can work against worms.

Beta-Tubulin Binding – Microtubule Disruption

Fenbendazole binds to beta-tubulin in parasite cells. This blocks the building of microtubules. Microtubules are needed for cell division, internal transport, shape, and nutrient handling. When the parasite cannot build them, it starts to fail at the cell level.

This leads to poor glucose uptake, poor energy use, loss of internal transport, and then parasite death. In simple terms, the parasite loses both its structure and its energy supply.

Selectivity – Why This Mechanism Targets Parasites More Than Mammalian Cells

Humans also have tubulin, so the obvious question is why fenbendazole does not harm human cells in the same way as usual antiparasitic exposure.

The reason is selectivity. Fenbendazole binds more strongly to parasite beta-tubulin than to mammalian beta-tubulin. That difference helps the drug act more on parasites than on normal human tissue.

Still, this selectivity is not absolute. At sufficiently high exposure levels, mammalian cells may also be affected. That is one reason why prolonged use and high-dose off-label use raise concern for liver injury and possible bone marrow toxicity.

Human-Specific Metabolism – 2025 Pharmacokinetic Finding

Human metabolism is an important part of this topic. A PubMed-listed study found that fenbendazole is extensively metabolized in human liver systems.

It also found that CYP2C19 and CYP2J2 play key roles in the formation of hydroxyfenbendazole. This supports the idea that humans may process the drug differently from veterinary species.

Some recent summaries also say that a 2025 study found humans may make more aminofenbendazole, which may be less active, while animals may make relatively more oxfendazole-like active metabolites.

But the exact 2025 claim could not be confirmed in a primary paper among the sources checked, so it should be treated with caution.

Antiparasitic Spectrum – Veterinary Profile

In veterinary medicine, fenbendazole has a broad spectrum against many gastrointestinal nematodes and some other parasites.

Veterinary sources list activity against roundworms, hookworms, whipworms, some lungworms, and some tapeworm species, depending on the host animal and product label. Panacur granules, for example, are marketed for dogs and cats infected with major nematodes and some cestodes.

There is also some veterinary use against Giardia in dogs and cats. But veterinary activity does not automatically mean approved human use. The spectrum tells us what the drug can do in animals. It does not create a human indication.

There was also an old human study from 1976 that looked at fenbendazole against Ascaris, hookworm, and Trichuris. That study is often cited because it is one of the few direct references to human parasites. But it is very old, small, and insufficient to support a modern approved human indication.

Pharmacokinetics of Fenbendazole 222mg in Humans – What Is Known

Human pharmacokinetic data for fenbendazole are limited. This is one of the biggest gaps in the topic. Unlike approved human drugs, fenbendazole has not undergone the usual large-scale human studies for dose-finding, blood-level testing, and long-term safety.

What is known suggests that fenbendazole has poor oral absorption and poor water solubility. The 2024 Anticancer Research review states that low water solubility is a major limitation of oral fenbendazole.

This helps explain why the drug is often more useful in the gut in animals, where high local intestinal levels may matter more than high blood levels.

Human liver metabolism also matters. A 2013 human microsome study found that CYP2C19 and CYP2J2 play important roles in fenbendazole metabolism. This means drug interactions are possible, and human exposure may change based on enzyme activity and other medicines.

Other Medicine:-

Dosage Information – 222mg Strength

There are no official FDA or EMA human dose guidelines for fenbendazole 222 mg. Any human dose reference is off-label, non-standard, and not supported by modern approval data. This is the most important dosing fact on the page.

Veterinary Reference Dosing – Canine (Same 222mg Base Unit)

The 222 mg number is strongly linked to veterinary use. Panacur-style canine dosing commonly uses 50 mg/kg for 3 days. In that system, about one 222 mg sachet corresponds roughly to a 10 kg dog.

That is part of why 222 mg became so widely recognized in informal use discussions.

Informal Human Protocol References (Non-Clinical – Documentation Only)

These references are not clinically validated. They come from anecdotal use, online communities, and discussions of non-standard protocols. They should not be treated as proven medical dosing.

Online discussions often mention:

How to Take Wormiza 222mg – General Guidance

If a physician decides to use fenbendazole off-label, general safety guidance is straightforward. Take it with food, because benzimidazole absorption is often better with a meal.

Swallow the tablet with water. Do not use veterinary sachets or animal products in place of a human-formulated tablet.

Baseline liver function tests should be checked first, and repeat monitoring should be planned during treatment. Alcohol should be avoided because both alcohol and fenbendazole increase liver stress.

Missed Dose

There is no standard human fenbendazole schedule, so there is no universal rule for missed doses.

If the tablet is being used in a physician-directed cycle, the safest step is to follow the doctor’s instructions for that exact plan. Do not double the next dose on the same day to make up for it.

Safety Profile & Side Effects – Wormiza 222mg

Fenbendazole has a long veterinary safety history, but human safety is less clear because formal human trials are limited. The strongest human safety concern is liver injury.

A 2024 report described severe histology-confirmed drug-induced liver injury in a woman who self-administered fenbendazole; her liver tests improved after the drug was stopped.

Commonly Reported Side Effects (Human Anecdotal + Veterinary Data)

Commonly reported problems include:

These are reported from anecdotal human use and from broader experience with the benzimidazole class. The gut effects are often mild and may improve when the drug is taken with food.

Serious Adverse Effects – Physician Awareness Required

The most important serious risk is hepatotoxicity. Published reports show that severe liver injury can happen in humans using fenbendazole off-label. Baseline and repeat ALT, AST, and bilirubin checks are important.

If liver enzymes rise clearly, or if jaundice, dark urine, or marked fatigue appear, the drug should be stopped, and a doctor should review the case.

A second concern is possible bone marrow suppression with prolonged or high exposure. This is not well defined in humans, but it is a known class concern and has been seen in animal use beyond normal label patterns. For longer use, CBC monitoring is sensible.

Warnings, Precautions & Contraindications

Several warnings are essential. First, fenbendazole is not FDA- or EMA-approved for human use. Second, there are documented human liver injury cases.

Third, people with pre-existing liver disease should avoid it or use it only with specialist review. Fourth, it should be avoided in pregnancy because benzimidazoles have shown embryo toxicity in animal studies.

Fifth, breastfeeding safety is not established. Sixth, use in children has no standard human dosing basis.

Drug interaction caution is also important. Human microsome studies show metabolism via CYP2C19 and CYP2J2, and secondary sources discuss broader CYP involvement.

This means other medicines may change fenbendazole exposure. A full medication review is important before any off-label use.

Fenbendazole 222mg vs Human-Approved Benzimidazoles

If the goal is treatment of a confirmed human parasite infection, albendazole and mebendazole are the stronger clinical choices because they are approved, studied, and supported by human guidelines.

MedlinePlus lists clear human uses for both drugs. WHO also includes them on the essential medicines list. Fenbendazole shares the same broad class mechanism, but it lacks the same level of human approval and human trial data.

In simple terms:

Storage Instructions

Store Wormiza 222 mg below 30°C. Keep it away from moisture, heat, and direct light. Keep the tablet in its original blister until use. Keep it out of the reach of children.

Check the expiry date before use. Unused tablets should be returned to a pharmacist when possible rather than thrown loosely into household waste.

Why Buy Fenbendazole 222 Mg from Actiza Pharmacy?

The main reason buyers look for a product like Wormiza 222 mg is not that its active ingredient differs from veterinary fenbendazole. It is because the formulation quality is different.

Veterinary sachets and animal products are not made or tested for human use. A pharmaceutical-grade tablet provides a defined amount of the active ingredient, standard excipients, and formal batch manufacturing controls. That is the real advantage of a product like Wormiza 222 mg.

Actiza positions Wormiza 222 mg as a WHO-GMP-manufactured, prescription-only product with a strength that matches the most commonly cited 222 mg reference amount.

The strongest reason to choose a pharmaceutical tablet over a veterinary sachet is the safety of formulation and dose definition, not the idea that the molecule itself is somehow different.

Conclusion

Wormiza 222 mg is a fenbendazole 222 mg tablet from the benzimidazole drug class. It works by binding to beta-tubulin, disrupting the parasite’s microtubules, and blocking energy use within the parasite.

The 222 mg strength is important because it matches a widely referenced veterinary base amount, but that does not make it an approved or validated human dose.

The two most important facts are these. First, fenbendazole is not approved for human use by the FDA or EMA. Second, human liver injury has been reported, so monitoring is essential in any off-label use.

Human-approved benzimidazoles, such as albendazole and mebendazole, remain the preferred first-line options for confirmed human parasitic infections.

FAQ